Welcome, Guest. Please login or register.
July 27, 2021, 08:37:38 pm

Login with username, password and session length


Members
Stats
  • Total Posts: 760760
  • Total Topics: 64550
  • Online Today: 277
  • Online Ever: 5484
  • (June 18, 2021, 11:15:29 pm)
Users Online
Users: 4
Guests: 254
Total: 258

Welcome


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Do I Have HIV?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Islatravir Plus Pifeltro Shows Promise as 2-Drug HIV Regimen  (Read 1125 times)

0 Members and 1 Guest are viewing this topic.

Offline Jim Allen

  • Administrator
  • Member
  • Posts: 17,406
  • Twitter @JimAllenDublin
    • HIV Lessons
Interesting update, we have to see how stage 3 turns out of course.

Poz.com write-up in full: https://www.poz.com/article/islatravir-plus-pifeltro-shows-promise-2drug-hiv-regimen

In short:

Quote

Islatravir Plus Pifeltro Shows Promise as 2-Drug HIV Regimen
A mid-stage trial showed the combo suppressed HIV, was well tolerated and resulted in a low rate of virologic failure.

The randomized, double-blind trial enrolled 121 people with HIV who had not previously taken treatment for the virus and had no known resistance to ARVs.

The study had two parts. In part one, the participants were randomized to receive islatravir at either 0.25 milligrams, 0.75 mg or 2.25 mg plus 100 mg of Pifeltro and 300 mg of lamivudine or to receive Delstrigo. Twenty-four weeks later, in part two, those who received islatravir and who had an undetectable viral load (below 50) stopped taking lamivudine and kept taking the remaining two-drug regimen of islatravir plus Pifeltro for another 24 weeks.

Findings presented at the 2019 International AIDS Society Conference on HIV Science in Mexico City indicated that 90% of those who took 0.75 mg of islatravir—the dose that will continue on to Phase III trials—had a fully suppressed viral load at the trial’s 48-week mark, compared with 84% of those on the three-drug regimen. These rates were considered comparable.
HIV 101 - Everything you need to know
HIV 101
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
HIV TasP
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP

 


Terms of Membership for these forums
 

© 2021 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.